Expert Venture Capitalists Panel to Discuss Investment Opportunities at Anti-Infectives Partnering & Deal-Making Summit (Mar. 5-7, Philadelphia)
Monrovia, CA, January 26, 2008 --(PR.com)-- 2005’s new trend of Big Pharma acquisitions of small companies developing monoclonal antibodies has sparked a renewed interest for investors in the anti-infectives space. Four leading expert Venture Capitalists will meet to discuss the various investment opportunities in infectious diseases at the 5th Anti-Infectives Partnering & Deal-Making Summit taking place on March 5-7 in Philadelphia, PA.
This investor panel will discuss what new and interesting compounds/technologies are attracting investors, the pros and cons from an investor perspective of small molecules and antibodies, some unique features of antibacterial development that are particularly attractive or unattractive from an investor perspective, and much more.
Eric C. Meltzer, Managing Director for Curtis Financial Group, will moderate a forty-five minutes panel entitled, “Investment Opportunities in the Anti-Infectives Space”. He will be joined by panelists Lisa Gray, Managing Partner for Phoenix IP Ventures; Jennifer H. Hartt, Director of Investments for Life Sciences Ben Franklin Technology Partners; and Gary Patou, Executive Partner at MPM Capital.
The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant anti-infective issues and deals that affect the industry.
Other topics to be covered at the 5th Anti-Infectives Partnering & Deal-Making Summit include New Anti-Infectives Technologies, Current Models of R&D Collaboration, New Pathogen Challenges, Future of Infectious Disease Therapeutics, and Developing Partnerships with Big Pharma.
Meet and hear presentations from experts of leading organizations such as AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Global Alliance for TB Drug Development, GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth, and many more. The full agenda is available online at www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
This investor panel will discuss what new and interesting compounds/technologies are attracting investors, the pros and cons from an investor perspective of small molecules and antibodies, some unique features of antibacterial development that are particularly attractive or unattractive from an investor perspective, and much more.
Eric C. Meltzer, Managing Director for Curtis Financial Group, will moderate a forty-five minutes panel entitled, “Investment Opportunities in the Anti-Infectives Space”. He will be joined by panelists Lisa Gray, Managing Partner for Phoenix IP Ventures; Jennifer H. Hartt, Director of Investments for Life Sciences Ben Franklin Technology Partners; and Gary Patou, Executive Partner at MPM Capital.
The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant anti-infective issues and deals that affect the industry.
Other topics to be covered at the 5th Anti-Infectives Partnering & Deal-Making Summit include New Anti-Infectives Technologies, Current Models of R&D Collaboration, New Pathogen Challenges, Future of Infectious Disease Therapeutics, and Developing Partnerships with Big Pharma.
Meet and hear presentations from experts of leading organizations such as AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Global Alliance for TB Drug Development, GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth, and many more. The full agenda is available online at www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
Contact
GTCbio
Nina Tran
626-256-6405 x 105
www.gtcbio.com
Nina Tran
626-256-6405 x 105
www.gtcbio.com
Contact
Categories